Changes of Serum Insulin-like Growth Factor-2 Response to Negative Symptom Improvements in Schizophrenia Patients Treated with Atypical Antipsychotics.

Current Medical Science
Xue-Lin ChaoYuan-Jian Yang

Abstract

Accumulating evidence suggests that a disruption of early brain development, in which insulin-like growth factor-2 (IGF-2) has a crucial role, may underlie the pathophysiology of schizophrenia. Our previous study has shown that decreased serum IGF-2 was correlated with the severity of psychopathology in patients with schizophrenia. Here we conducted a prospective observation trial to investigate the effects of atypical antipsychotics on serum IGF-2 level and its relationship with clinical improvements in schizophrenia patients. Thirty-one schizophrenia patients with acute exacerbation and 30 healthy individuals were recruited in this study. Psychiatric symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) and serum IGF-2 levels were determined using ELISA. We found that schizophrenia patients with acute exacerbation had lower serum IGF-2 levels than control individuals at baseline (P<0.05). After 2 months of atypical antipsychotic treatment, a significant improvement in each PANSS subscore and total score was observed in patients (all P<0.01), and the serum IGF-2 levels of patients were significantly increased compared with those at baseline (203.13±64.62 vs. 426.99±124.26 ng/mL; t =-5.044, P<0.001). Cor...Continue Reading

References

Sep 1, 1992·The British Journal of Psychiatry : the Journal of Mental Science·V PeraltaM J Cuesta
Jan 1, 1996·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·B GallhoferH Gruppe
Aug 21, 2003·European Psychiatry : the Journal of the Association of European Psychiatrists·Ann M Mortimer
Jun 23, 2004·Lancet·Kim T Mueser, Susan R McGurk
Mar 24, 2005·The International Journal of Neuropsychopharmacology·Neil D WoodwardDavid H Zald
Sep 1, 2005·Endocrine Reviews·V C RussoG A Werther
Jul 20, 2007·Clinical Chemistry and Laboratory Medicine : CCLM·Abayomi O AkanjiHasmukh R Fatania
Sep 17, 2008·Journal of Clinical Psychopharmacology·Menahem I KrakowskiKaren A Nolan
Jul 30, 2009·Neuropsychology Review·Barton W PalmerRobert K Heaton
Aug 25, 2009·Lancet·Jim van Os, Shitij Kapur
Jan 29, 2011·Nature·Dillon Y ChenCristina M Alberini
Sep 29, 2011·JAMA : the Journal of the American Medical Association·Alicia Ruelaz MaherPaul G Shekelle
Mar 21, 2012·Nature Reviews. Neuroscience·Ana M Fernandez, Ignacio Torres-Alemán
Jun 20, 2012·Frontiers in Neuroendocrinology·John O'Kusky, Ping Ye
Aug 1, 2002·European Psychiatry : the Journal of the Association of European Psychiatrists·F Müller-Spahn
Dec 1, 2014·Psychiatry Research·Kayla A ChaseRajiv P Sharma
May 10, 2015·British Medical Bulletin·John Lally, James H MacCabe
Jan 19, 2016·Lancet·Michael J OwenPreben B Mortensen
Jul 13, 2016·Schizophrenia Research·Sonia Dollfus, John Lyne
Oct 28, 2016·Nature Neuroscience·Menachem FromerPamela Sklar
Jul 20, 2017·Therapeutics and Clinical Risk Management·Marco SolmiAndré F Carvalho
Jan 3, 2018·Progress in Neuro-psychopharmacology & Biological Psychiatry·Chao ZhaoNan Hong
Aug 4, 2018·Current Medical Science·Qian-Qian HanJian-Guo Chen
Dec 24, 2018·Schizophrenia Bulletin·Dinesh K ShuklaL Elliot Hong
Jan 31, 2019·The American Journal of Psychiatry·Roscoe O BradyMark A Halko

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here